TKI258 has been and continues to be tested in clinical trials including malignancies linked to FGFR genetic alterations (breast cancer, renal cell carcinoma and bladder cancer) and its other targets (such as KIT in gastrointestinal stromal tumours/GIST) (Andre et al., 2013, Konecny et al., 2013, Mazzola et al., 2014, Kang et al., 2013). This evidence concerns the gene KIT and urinary bladder cancer.